Bleeding Disorders
From the Journals
Hemophilia adherence tied to perception of disease
Adherence to prophylaxis is generally high, but quality of life and disease coping matter.
News
Emicizumab granted priority review for hemophilia A without inhibitors
The US Food and Drug Administration (FDA) has granted priority review for emicizumab (Hemlibra®) for adults and children with hemophilia A without...
News
Emicizumab gets priority review for hemophilia A without inhibitors
The Food and Drug Administration is expected to make an approval decision on emicizumab in October 2018.
Conference Coverage
Perioperative rVWF alone sufficient for some VWD patients
GLASGOW—Recombinant von Willebrand factor (rVWF) alone can be sufficient as perioperative management for some patients with severe von Willebrand...
Conference Coverage
Emicizumab controls bleeding regardless of inhibitors
GLASGOW—Emicizumab prophylaxis provides “clinically meaningful” control of bleeding whether or not patients have factor VIII inhibitors, according...
From the Journals
Tailored hemophilia prophylaxis could cut costs
Tailored frequency-escalated prophylaxis resulted in less use of recombinant factor VIII.
Conference Coverage
Gene therapy reduces ABR, AIR in hemophilia B
GLASGOW—New research suggests the gene therapy SPK-9001 can reduce bleeding and the need for factor IX infusions in patients with hemophilia B....
Conference Coverage
N9-GP has better PK profile than rFIXFc, team says
GLASGOW—Nonacog beta pegol (N9-GP) has a better pharmacokinetic (PK) profile than recombinant factor IX-Fc fusion protein (rFIXFc), according to...
Conference Coverage
Therapy can extend half-life of FVIII
GLASGOW—Preliminary data suggest an investigational therapy can extend the half-life of factor VIII (FVIII) in patients with severe hemophilia A...
News from the FDA/CDC
FDA approves Doptelet for liver disease patients undergoing procedures
Avatrombopag (Doptelet) is the first drug approved for thrombocytopenia in adults who have chronic liver disease and are undergoing a procedure....
Conference Coverage
Emicizumab reduces bleeding in hemophilia A
GLASGOW—Final results from the HAVEN 3 study suggest emicizumab prophylaxis can reduce bleeding in hemophilia A patients without factor VIII...